Related Experiment Video
Updated: Jan 9, 2026
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Immunotherapy for Glioblastoma: A Focus on PD-1/PD-L1 Inhibitors
Vasiliki Zoi1, Vasiliki Galani2, Chrissa Sioka1,3
1Neurosurgical Institute, University of Ioannina, 45500 Ioannina, Greece.
Abstract:
Glioblastoma is the most common and lethal type of tumor of the central nervous system, with an average survival of 15 months after first diagnosis. Immune checkpoint inhibitors (ICIs) have been largely investigated for their ability to harness the immune system to combat tumors. However, their efficacy varies a lot depending on tumor type. In glioblastoma, PD-1/PD-L1 immunotherapy has been explored in various studies; however, the unique immunosuppressive environment in the brain and the presence of the blood-brain barrier as well as the large intratumoral heterogeneity have limited its efficacy considerably. In order to improve the clinical efficacy of ICIs, it is important to delve into the different factors affecting the response rate in GBM. Herewith, we summarize the most common causes of resistance to anti-PD-1/PD-L1 immunotherapy as well as possible ways of enhancing its efficacy, particularly through combination with other therapeutic agents in the preclinical and clinical setting. Furthermore, we provide an insight into the most promising methods for modulating the blood-brain barrier, as well as the growing role of molecular imaging and radiogenomics in this field.
Insights
Glioblastoma treatment with PD-1/PD-L1 immunotherapy shows limited efficacy due to the brain's unique environment. Combining therapies and overcoming the blood-brain barrier are key to improving glioblastoma survival rates.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer Research
Background:
- Glioblastoma is a lethal brain tumor with poor prognosis.
- Immune checkpoint inhibitors (ICIs) show variable efficacy in cancer treatment.
- PD-1/PD-L1 immunotherapy faces challenges in glioblastoma due to the immunosuppressive brain microenvironment and blood-brain barrier.
Purpose of the Study:
- To summarize factors limiting PD-1/PD-L1 immunotherapy efficacy in glioblastoma.
- To explore strategies for enhancing immunotherapy response in glioblastoma.
- To review advancements in overcoming the blood-brain barrier and the role of imaging in glioblastoma treatment.
Main Methods:
- Literature review of preclinical and clinical studies on glioblastoma immunotherapy.
- Analysis of resistance mechanisms to PD-1/PD-L1 therapy.
- Investigation of combination therapies and blood-brain barrier modulation techniques.
Main Results:
- Intratumoral heterogeneity and the immunosuppressive tumor microenvironment are major resistance factors.
- Combination therapies, including agents targeting the tumor microenvironment, show promise.
- Blood-brain barrier penetration and molecular imaging are crucial for therapeutic enhancement.
Conclusions:
- Improving glioblastoma immunotherapy requires addressing resistance mechanisms and enhancing drug delivery.
- Combination strategies and advanced imaging techniques are vital for future treatment paradigms.
- Further research into blood-brain barrier modulation and radiogenomics is essential for advancing glioblastoma treatment.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...